Angiotensin Receptor Blockers (ARBs)
Start with the big picture
ARBs competitively block AT1 receptors, reducing angiotensin II effects such as vasoconstriction and aldosterone release. Unlike ACE inhibitors, they do not inhibit bradykinin breakdown, so cough is negligible and angioedema is less common. The class includes agents such as losartan, valsartan and candesartan, with differences in formulations and pharmacology. Clinical uses include hypertension, heart failure and proteinuric kidney disease. Safe use requires attention to potassium, serum creatinine, blood pressure, interacting medicines and situations where renal function may be at risk. Pregnancy and lactation are contraindications. This preview introduces the class; the full lesson develops its mechanisms, clinical applications, precautions and comparative features.
What you'll learn
- Describe how ARBs block AT1 receptors and affect the renin–angiotensin–aldosterone system.
- Identify representative ARBs and selected formulation or pharmacology differences.
- Summarize major clinical uses and renal-protective effects of ARBs.
- Recognize important adverse effects, contraindications and drug interactions.
- Explain the role of potassium and creatinine monitoring during treatment.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
